Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
Marc HumbertVallerie McLaughlinJ Simon R GibbsMardi Gomberg-MaitlandMarius M HoeperIoana R PrestonRogério de SouzaAaron WaxmanPilar Escribano SubiasJeremy FeldmanGisela MeyerDavid MontaniKaren M OlssonSolaiappan ManimaranJennifer BarnesPeter G LindeJanethe de Oliveira PenaDavid B Badeschnull nullPublished in: The New England journal of medicine (2021)
Treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background therapy for pulmonary arterial hypertension. (Funded by Acceleron Pharma; PULSAR ClinicalTrials.gov number, NCT03496207.).